公开(公告)号：US20220143179A1

公开(公告)日：2022-05-12

申请号：US17436146

申请日：2020-03-04

Applicant: NORTH CAROLINA STATE UNIVERSITY

Inventor： Zhen GU ,  Huitong RUAN ,  Quanyin HU

IPC: A61K39/395 ,  A61K9/06 ,  C07K16/28 ,  A61K31/7068 ,  A61K31/706 ,  A61K31/353 ,  A61K31/245 ,  A61K31/405 ,  A61K31/711 ,  A61K31/7084 ,  A61K47/32 ,  A61K47/24 ,  A61P35/00

Abstract: Disclosed are compositions comprising dual bioresponsive hydrogels and methods of their use.

公开(公告)号：US11298320B2

公开(公告)日：2022-04-12

申请号：US17330209

申请日：2021-05-25

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： Ian MacLachlan ,  Lloyd B. Jeffs ,  Lorne R. Palmer ,  Cory Giesbrecht

IPC: A61K9/127 ,  A61K47/10 ,  A61K47/24 ,  A61K47/44 ,  A61K31/7088 ,  A61K31/7084

Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.

公开(公告)号：US20220096515A1

公开(公告)日：2022-03-31

申请号：US17488061

申请日：2021-09-28

Applicant: Huntington Medical Research Institutes

Inventor： Anju Vasudevan

IPC: A61K31/7084 ,  A61K9/00

Abstract: Methods of treatment and pharmaceutical formulations configured to prevent psychiatric diseases and/or disorders in offspring are provided. The methods and treatments use a regulator of angiogenesis pathways. The regulator can restore GABA secretion and neuronal migration. The regulator may be administered during pregnancy of an individual, thus allowing proper development of a fetal brain.

公开(公告)号：US11248020B2

公开(公告)日：2022-02-15

申请号：US16615966

申请日：2018-05-22

Applicant: Viktor Veniaminovich Tets ,  Georgy Viktorovich Tets

Inventor： Viktor Veniaminovich Tets ,  Georgy Viktorovich Tets

IPC: C07H21/00 ,  A61P9/10 ,  A61P25/28 ,  A61P37/06 ,  A61P35/00 ,  C07H21/04 ,  A61K31/711 ,  A61K31/7084 ,  A61K31/7105 ,  A61K31/7052 ,  A61K31/7088 ,  A61K31/7068 ,  A61K31/708 ,  A61K31/7076 ,  A61K31/7072 ,  C07H21/02

Abstract: The invention relates to pharmaceutical compositions comprising mono- and/or oligonucleotides, dosage forms, and methods for treating and preventing diseases.

公开(公告)号：US11246855B1

公开(公告)日：2022-02-15

申请号：US17378625

申请日：2021-07-16

Applicant: Matthias W Rath

Inventor： Madhurima Chatterjee ,  Matthias W Rath ,  Aleksandra Niedzwiecki ,  Anna Goc

IPC: A61K31/51 ,  A61K33/00 ,  A61K33/22 ,  A61K33/30 ,  A61K36/54 ,  A61K36/87 ,  A61K31/375 ,  A61K31/047 ,  A61K31/525 ,  A61K31/455 ,  A61K31/197 ,  A61K31/4415 ,  A61K31/4188 ,  A61K31/714 ,  A61K31/519 ,  A61K31/07 ,  A61K31/122 ,  A61K31/593 ,  A61K36/61 ,  A61K36/82 ,  A61K31/198 ,  A61K33/06 ,  A61K33/32 ,  A61K33/18 ,  A61K31/575 ,  A61K31/7004 ,  A61K31/7084 ,  A61K36/282 ,  A61K36/185 ,  A61K31/385 ,  A61K31/355

Abstract: A threefold decrease in α-amylase inhibition, increase in insulin secretion and glucose uptake increase by the pharmaceutical composition of several naturally occurring substances and vitamins were observed when compared to the control cells, and a c.a. 1-1.5 fold decrease when compared to the positive control. More specifically Mix A and Mix B applied together with VitaminD+K2 shows significant effect on increased insulin secretion and glucose uptake by cells.

公开(公告)号：US11203610B2

公开(公告)日：2021-12-21

申请号：US16225996

申请日：2018-12-19

Applicant: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.

Inventor： Gabriel Birkus ,  Ondrej Pav ,  Tomas Jandusik ,  Ivan Rosenberg ,  Radim Nencka

IPC: C07H21/00 ,  C07H21/04 ,  C07H19/213 ,  A61P35/00 ,  A61K31/7084 ,  A61K31/7016 ,  C07H21/02 ,  A61P31/12

Abstract: The present disclosure relates to 2′3′ cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.

公开(公告)号：US20210353760A1

公开(公告)日：2021-11-18

申请号：US16958463

申请日：2018-12-28

Applicant: INVIVOGEN

Inventor： Thierry LIOUX ,  Fabienne VERNEJOUL ,  Cédric BOULARAN ,  Michèle TIRABY

IPC: A61K47/54 ,  A61K47/68 ,  A61K47/65 ,  A61K47/64 ,  A61K45/06 ,  A61K31/7084

Abstract: The present invention provides a Pro-cyclic dinucleotide (Pro-CDN) comprising a STING agonist cyclic dinucleotide which is coupled to a linker system. The Pro-CDNs of the present invention can be metabolized at a targeted site into CDNs and exert their full immunomodulatory effects at said targeted site. The present invention also provides conjugates wherein a Pro-CDN is conjugated to a Biologically Active Molecule (BAM) such as e.g. a cytotoxic molecule, a lipid, a protein, a peptide, a nucleic acid, a sugar or a PRR ligand. The invention provides also methods related to the use of such compounds to perform their activities at their targeted sites, to exert cytotoxic, cytostatic or immunomodulatory effects, to treat or to prevent diseases such as cancers, immunological disorders or infections.

公开(公告)号：US20210346326A1

公开(公告)日：2021-11-11

申请号：US17284993

申请日：2019-10-14

Applicant: The Wistar Institute of Anatomy and Biology

Inventor： Dmitry I. Gabrilovich

IPC: A61K31/185 ,  A61K31/7076 ,  A61K31/513 ,  A61K31/438 ,  A61K31/7084 ,  A61K31/436 ,  A61K45/06 ,  G01N33/574

Abstract: A method of identifying a population of PMN-MDSC-Like Cells (PM-LCs) distinguishable from myeloid derived suppressor cells (PMN-MDSCs). A method for treating a cancer comprising identifying PM-LCs and/or administering an agent that alters neutrophil migration to reduce or inhibit tumor cell seeding, tumor metastasis, or metastatic niche formation in a subject. Compositions for use in diagnosing and treating cancer that comprise antagonists and/or inhibitors of genes and cellular process to alter PM-LC activity.

公开(公告)号：US20210283197A1

公开(公告)日：2021-09-16

申请号：US17260126

申请日：2019-07-17

Applicant: FERRING B.V.

Inventor： KENNETH F. BLOUNT ,  GREGORY J. FLUET

IPC: A61K35/741 ,  A61K9/00 ,  A61K45/06 ,  A61K39/395 ,  A61K9/48 ,  A61K31/7084 ,  A61P35/00

Abstract: Microbiota restoration therapy compositions and methods for making and using microbiota restoration therapy compositions are disclosed. One example method is a method for enhancing the immune system of a patient. The method may include administering a microbiota restoration therapy composition to a patient with a primary condition. The method may also include administering a treatment for the primary condition to the patient. The treatment may be designed to treat the primary condition.

公开(公告)号：US11116784B2

公开(公告)日：2021-09-14

申请号：US16079963

申请日：2017-02-21

Applicant: Beth Israel Deaconess Medical Center, Inc.

Inventor： Samir M. Parikh

IPC: A61K31/7084 ,  A61K31/4409 ,  A61K31/44 ,  A61P41/00 ,  A61K31/403 ,  A61K31/455 ,  A61K31/706 ,  A61K31/711 ,  A61P13/12 ,  C12N15/113 ,  A61P9/10 ,  G01N33/50

Abstract: Methods of treating ischemic tissue injury or kidney disease, e.g., delayed graft function, that include administering a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist.